CTRI/2023/01/048670
Active, not recruiting
Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: L271- Localized skin eruption due to drugs and medicaments taken internally
- Sponsor
- OnQuality Pharmaceuticals (USA) LLC
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The subjects will be included in the study based on the following criteria:
- •1\) Patient must be age \= 18 years.
- •2\) Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi\-based anticancer therapy with stable dosage for \= 1 week. This treatment may be VEGFRi monotherapy or VEGFRi\-based combination therapy, so long as it does not include prohibited therapies.
- •3\) Patient must have shown signs of HFSR that meet the IGA\-HFSR criteria of grade 3 or higher.
- •4\) Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue on the same dose.
- •5\) Patient is able to use topical medications and complete questionnaires reliably.
- •6\) ECOG performance score \= 2
- •7\) Patient must have the ability to understand and the willingness to sign a written informed consent prior to study entry.
Exclusion Criteria
- •The subjects will be excluded from the study based on the following criteria:
- •1\) Patient with unresolved hand\-foot skin disorders (CTCAE grade 2 or higher) due to other medications within 4 weeks prior to study entry.
- •2\) Patient who is using other topical medications in the hands or feet area and cannot stop such usage ahead of randomization.
- •3\) Patient who is on concurrent cancer medications that can cause skin reactions in hands or feet, such as capecitabine, pegylated liposomal doxorubicin, 5\-fluorouracil, dabrafenib, vemurafenib, doxorubicin, docetaxel, cytarabine.
- •4\) Patient who is under uncontrolled intercurrent illness including, but not limited to, inadequately controlled nausea, vomiting, diarrhea or other conditions which may contribute to hypovolemia, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, uncontrolled hypotension (including orthostatic hypotension) or hypertension, cardiac arrhythmia, or psychiatric illness and social situations that would limit compliance with study requirements.
- •5\) Patient who has contraindication with the active compound, including severe anemia, increased intracranial pressure, known hypersensitivity.
- •6\) Patient who has other skin disorders that will affect the efficacy evaluation on hands and feet area, including but not limited to, tinea of feet and hands, hand/foot eczema, palmoplantar pustulosis, palmoplantar keratosis, acrodermatitis continua etc.
- •7\) Patient who used of phosphodiesterase type 5 (PDE5\) inhibitors such as sildenafil, vardenafil, and tadalafil within past 7 days.
- •8\) Patient with significantly abnormal lab test:
- •Inadequate hematologic function as indicated by:
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A clinical trial to study the safety and efficacy of a monoclonal antibody in patients with active psoriasisCTRI/2008/091/000296Biocon Limited
Not yet recruiting
Phase 2
Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR inhibitor-Associated HFSR in Cancer Patients.Health Condition 1: L271- Localized skin eruption due to drugs and medicaments taken internallyCTRI/2021/07/034694ONQUALITY PHARMACEUTICALS USA LLC
Active, not recruiting
Phase 1
A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination with an mRNA or Vector Vaccine in Patients under Immunosuppressive Therapy no or reduced Responds to Standard mRNA SARS-CoV-2 (Covid-19) VaccinatioVaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficienciesTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2021-002693-10-ATMedical University of Vienna, Department for Internal Medicine III, Division of Rheumatology300
Active, not recruiting
Phase 1
Clinical study to review how safe and how effective IMR-687 is in subjects with Sickle Cell DiseaseSickle Cell DiseaseMedDRA version: 20.0Level: PTClassification code 10043395Term: Thalassaemia sickle cellSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2019-004471-39-ITIMARA Inc.99
Not yet recruiting
Phase 2
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell DiseaseThe population for this study includes subjects with the following forms of SCD: homozygous sickle hemoglobin (HbSS), sickle-ß° (HbSB°) thalassemia, and sickle-ß? (HbSB?) thalassemia.Sickle cellLBCTR2020083421IMARA, Inc.99